Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$12.09 -3.6%	$7.91	$4.11 ▼ $28.68	$79.56M	2.85	159,439 shs	34,405 shs
IMRX Immuneering	$1.90 -3.1%	$1.50	$1.00 ▼ $3.83	$68.37M	0.01	2.36 million shs	175,598 shs
PDSB PDS Biotechnology	$1.75 -2.2%	$1.34	$0.85 ▼ $4.42	$79.99M	1.27	495,109 shs	327,198 shs
SLGL Sol-Gel Technologies	$7.52 +9.0%	$6.83	$3.34 ▼ $16.50	$20.95M	1.1	32,904 shs	102,998 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	0.00%	+6.80%	+54.41%	+108.45%	+52,926.32%
IMRX Immuneering	0.00%	-10.80%	+47.86%	+18.75%	+23.38%
PDSB PDS Biotechnology	0.00%	+3.55%	+29.63%	+42.28%	-40.27%
SLGL Sol-Gel Technologies	0.00%	+3.87%	-1.96%	+35.23%	-3.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBRX Forte Biosciences	3.0407 of 5 stars	3.5	3.0	2.6	1.7	1.3
IMRX Immuneering	3.0356 of 5 stars	3.3	2.0	2.7	3.3	1.3
PDSB PDS Biotechnology	1.5105 of 5 stars	3.7	1.0	2.8	0.0	0.0
SLGL Sol-Gel Technologies	3.0202 of 5 stars	3.5	5.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	3.00	Buy	$61.00	404.55% Upside
IMRX Immuneering	2.50	Moderate Buy	$14.33	654.39% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	414.29% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	431.91% Upside

Current Analyst Ratings Breakdown

Latest SLGL, FBRX, PDSB, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/10/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/1/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $61.00
3/27/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $13.00
3/24/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/21/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$24.30 per share	N/A
IMRX Immuneering	$320K	213.67	N/A	N/A	$3.09 per share	0.61
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.84 per share	N/A
SLGL Sol-Gel Technologies	$12.10M	1.73	N/A	N/A	$1.67 per share	4.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$31.48M	-$16.29	N/A	N/A	N/A	N/A	-151.43%	-118.92%	8/13/2025 (Estimated)
IMRX Immuneering	-$53.47M	-$1.96	N/A	N/A	N/A	N/A	-79.19%	-69.08%	8/5/2025 (Estimated)
PDSB PDS Biotechnology	-$42.94M	-$0.94	N/A	N/A	N/A	N/A	-139.57%	-67.22%	8/12/2025 (Estimated)
SLGL Sol-Gel Technologies	-$27.24M	-$4.70	N/A	N/A	N/A	-81.75%	-27.17%	-22.49%	8/14/2025 (Estimated)

Latest SLGL, FBRX, PDSB, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A
3/27/2025	Q4 2024	PDSB PDS Biotechnology	-$0.29	-$0.21	+$0.08	-$0.21	N/A	N/A
3/20/2025	Q4 2024	IMRX Immuneering	-$0.42	-$0.58	-$0.16	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	2.06	2.06
IMRX Immuneering	N/A	7.99	7.99
PDSB PDS Biotechnology	0.55	2.84	2.84
SLGL Sol-Gel Technologies	N/A	5.81	5.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
IMRX Immuneering	67.65%
PDSB PDS Biotechnology	26.84%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	5.90%
IMRX Immuneering	22.90%
PDSB PDS Biotechnology	9.20%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
IMRX Immuneering	60	35.99 million	23.29 million	Not Optionable
PDSB PDS Biotechnology	20	45.71 million	33.86 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	9.33 million	Optionable

SLGL, FBRX, PDSB, and IMRX Headlines

Recent News About These Companies

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.com

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

April 1, 2025 | tipranks.com

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

February 25, 2025 | zacks.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

February 7, 2025 | finance.yahoo.com

Sol Gel Technologies Ltd (SLGL) Stock Trading Recap

December 26, 2024 | bovnews.com

Is SolGel Technologies (SLGL) a Great Value Stock Right Now?

December 25, 2024 | zacks.com

Sol-Gel Technologies Reports Strong Q3 2024 Results

November 21, 2024 | markets.businessinsider.com

Sol-Gel announces 180-day extension to regain compliance with Nasdaq

November 21, 2024 | markets.businessinsider.com

SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know

November 20, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL, FBRX, PDSB, and IMRX Company Descriptions

Forte Biosciences NASDAQ:FBRX

$12.09 -0.45 (-3.59%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$12.02 -0.07 (-0.58%)

As of 06/13/2025 04:08 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Immuneering NASDAQ:IMRX

$1.90 -0.06 (-3.06%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.07 (+3.89%)

As of 06/13/2025 07:37 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

PDS Biotechnology NASDAQ:PDSB

$1.75 -0.04 (-2.23%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.29%)

As of 06/13/2025 07:02 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Sol-Gel Technologies NASDAQ:SLGL

$7.52 +0.62 (+8.99%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.36 -0.15 (-2.06%)

As of 06/13/2025 07:58 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time